William Hunter

Impressive initiative by Daicel Chiral Technologies (India) Pvt Ltd in biosimilar analytical comparability. Robust characterization — HOS, charge variants, PTM & glycosylation — is key to regulatory confidence and faster development. Strong science driving better biologics. #Biosimilars #AnalyticalScience #Biologics

36

Innovation in biotech takes many forms — and Enlivex Therapeutics (Nasdaq: ENLV) is offering a powerful example of what progress can look like in 2025. This year, Enlivex announced positive 6-month topline data from their final phase of development, demonstrating durable and persistent pain reduction, along with improved function, in patients with moderate to severe knee osteoarthritis. They also introduced a forward-thinking digital asset treasury strategy that incorporates a token component into their stock structure. A bold move that reflects the evolving landscape of biotech financing. Those major milestones highlight both scientific momentum and strategic vision. Congratulations to the entire Enlivex team on an exceptional end to 2025. We’re excited to see what comes next. Discover our full Enlivex case study here: https://lnkd.in/dPQVaCv9

4

𝐏𝐫𝐞𝐯𝐢𝐬𝐢𝐨𝐧 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐥𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐁𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐃𝐫𝐮𝐠-𝐒𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐓𝐞𝐬𝐭 𝐟𝐨𝐫 𝐀𝐌𝐋 Acute Myeloid Leukemia (#AML) remains one of the most aggressive and heterogeneous blood cancers, where timely and precise treatment decisions are critical. We are proud to announce the launch of our AML Drug Screening Test, powered by our proprietary 𝐏𝐫𝐞𝐯𝐢𝐬𝐢𝐨𝐧𝐎𝐧𝐞 platform. PrevisionOne represents the culmination of a decade of technical and clinical innovation.  By turning complex drug-response data into clear, functional guidance, the AML Drug Screening Test empowers oncologists with 𝐟𝐚𝐬𝐭𝐞𝐫, 𝐞𝐯𝐢𝐝𝐞𝐧𝐜𝐞-𝐛𝐚𝐜𝐤𝐞𝐝, 𝐩𝐚𝐭𝐢𝐞𝐧𝐭-𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬. ✅ Tests patient-derived malignant and non-malignant cells against 100 drugs and drug combinations ✅ Delivers actionable clinical insights in as little as 72 hours ✅ Backed by two clinical trials (EXALT-1 and DARTT-1), showing improved patient survival with top-recommended therapies ✅ Built on collaborations with leading hospitals across Switzerland, Germany, and Austria, based on 300+ patient samples 𝐓𝐞𝐬𝐭 𝐰𝐢𝐭𝐡 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧, 𝐭𝐫𝐞𝐚𝐭 𝐰𝐢𝐭𝐡 𝐜𝐨𝐧𝐟𝐢𝐝𝐞𝐧𝐜𝐞: 𝐨𝐮𝐫 𝐦𝐢𝐬𝐬𝐢𝐨𝐧 𝐢𝐬 𝐭𝐨 𝐡𝐞𝐥𝐩 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐚𝐠𝐠𝐫𝐞𝐬𝐬𝐢𝐯𝐞 𝐜𝐚𝐧𝐜𝐞𝐫𝐬 𝐫𝐞𝐜𝐞𝐢𝐯𝐞 𝐭𝐡𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐭𝐡𝐚𝐭’𝐬 𝐫𝐢𝐠𝐡𝐭 𝐟𝐨𝐫 𝐭𝐡𝐞𝐦, 𝐬𝐨𝐨𝐧𝐞𝐫. 🔗 For more information visit our website: www.previsionmedicine.com  👇 Read the full press releases below: #PrecisionOncology #CancerResearch #AML #DrugScreening #FunctionalPrecisionMedicine #PersonalizedMedicine #OncologyInnovation #ClinicalResearch #HealthcareInnovation

44

4 Comments

TransThera | 药捷安康 Signs Up to $881.5M Deal with Neurocrine Biosciences to Advance NLRP3 Inhibitors  #transthera #neurocrinebiosciences #nlrp3inhibitors #preclinical #researchcollaboration #nlrp3technology #milestones #pharma https://lnkd.in/ggw9Z-ZP

3

Grace has joined the newest cohort of the Charles River Laboratories Cell & Gene Therapy Incubator Program, enabling us to advance our proprietary superparamagnetic silica technology and unlock novel uses for this platform. “The incubator program provides a focused environment to fast-track our proof of concept for new applications in therapeutic-grade pDNA purification. This collaboration is a strategic step to amplify our impact and deliver life-saving solutions to patients,” said Brenda Kelly, President of the Material Technologies business at Grace. Read the full press release here: https://lnkd.in/dJshDNXQ

46

1 Comment

📣 Exciting news from BIO 2025! 📣 We’re thrilled to share that Mosaic Biosciences is now a preferred #CRO partner for AbTherx! This partnership brings together two teams of experienced drug hunters to offer a fully integrated antibody discovery engine - from high quality in vivo discovery to custom in vitro engineering, developability profiling, and functional assay development. As part of this collaboration, Mosaic will now offer access to AbTherx’s industry- leading proprietary humanized mice for antibody discovery, expanding our in vivo capabilities and enabling seamless discovery- to- IND support. Together, Mosaic and AbTherx are making it easier for biopharma teams to access fit for purpose antibodies supported by the deep scientific collaboration and quality execution both teams are known for. Both teams will be at #BIO this week- let us know if you’d like to meet! #antibodydiscovery #drugdiscovery #biotechpartnership #BIO2025 #mosaicbio #abtherx #PRO #humanizedmousemodels #ATLAS

62

Funding Opportunity Highlight The NIAMS Exploratory Clinical Trial Grants in Arthritis, Musculoskeletal, and Skin Diseases (R61) program supports short-term, early-phase clinical trials designed to accelerate promising therapies into clinical application. This opportunity funds proof-of-concept and Phase I/II studies evaluating drugs, biologics, devices, or rehabilitation and behavioral interventions to improve function and outcomes in patients with rheumatic, musculoskeletal, or skin conditions. 💡 Who this targets: Researchers in rehabilitation medicine, orthopedics, dermatology, rheumatology, and clinical trial design, particularly those ready to translate early research findings into patient-centered impact. 🔍 The link to the full funding opportunity is in the comments. Submit a collaboration inquiry with Geneva to learn how we can support your proposal, build strategic partnerships, and navigate submission requirements. 👉 Let’s advance your research together. https://bit.ly/47SXWmx

7

1 Comment